Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance

NEW YORK, Dec. 11 /PRNewswire-FirstCall/ -- -- Innovation and Patient-Centered Approach Expected to Drive Future Success -- Lilly Climbs into Top 10 Pharmaceutical Companies in Worldwide Sales and Is Fastest Growing in U.S. -- FIPNet Strategy Expands Global Reach and...

GE Healthcare enjoys robust growth in first quarter

Waukesha, Wis. The vital signs are good for the UK-based parent company of GE Healthcare Technologies , which reported healthy profits and revenues during the first quarter of 2006. Profits for General Electric Co.'s GE Healthcare division, which includes GE Healthcare Technologies, Waukesha...

Age of empowered individuals: People power behind robust computing

Editor's Note: This is the text of Chris Shipley's keynote speech given to open the recent DEMO 2007 Conference in Palm Desert, Calif. I shouldn't be surprised by the energy in this room today, and neither should you. You are at the very center of an exciting shift in the information technol...

A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders

Purpose The peroxisome is a cellular organelle that plays an important role in a number of functions, including the beta-oxidation of very long chain fatty acids (VLCFA). Peroxisomal disorders are characterized by impaired, reduced or total absence of peroxisomes in cells, wh...

Using the TripleMaster PCR System for Robust Amplification of GC-Rich DNA Templates

Scott Tarpinian Eppendorf 5 Prime, Boulder, CO, USA Introduction The polymerase chain reaction (PCR*) is a powerful and sensitive technique used by scientists to amplify large quant...

prostar RT-PCR Systems for Robust High-Fidelity RNA Amplification

Powerful high-fidelity RT-PCR systems in two convenient formats Michael Borns Janice Cline Kris Connors Ronda Allen Holly Hogrefe Stratagene Stratagenes prostar RT-PCR systems are powerful systems that permit efficient, high-fidelity amplification of RNA in t...

Synthetech Reports First Quarter Fiscal 2010 Results

...sts. We remain guardedly optimistic about overall performance for the balance of fiscal year 2010 based on a reasonable $4.6 million order backlog, a robust project pipeline providing us with additional market opportunities, and better than expected strength in our biopharmaceutical customer base. In addi...

Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti-Infection Treatments

... that evaluated numerous contract manufacturing organizations in both Europe and the United States. Eden Biodesign will undertake the development of a robust manufacturing process for the product leading to cGMP production for supplying clinical studies. Omnio Healer has also assessed Eden Biodesign as a po...

CapitalBio Corporation and VigeneTech Inc. Have Announced the Launch of a Fully Integrated Microarray Solution Platform

...paralleled speed, sensitivity, and image data of superior accuracy. VigeneTech's customized quality control processes and flexible architecture ensure robust automation while maintaining the flexibility to meet the quality and performance demands of clinical and pre-clinical array applications. "The ...

Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City

...development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve...

Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets

...development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve...

Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference

...mall molecule compounds directed at multiple high value cancer stem cell targets of a variety of hematological and solid cancers. Stemline has built a robust discovery platform called "StemScreen(R)" which the Company has utilized to identify multiple compounds that target and impair cancer stem cells. For ...

Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009

...armaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty bus...

Ricardo Launches Consortium to Evaluate Lubricant Challenges of Future Low Carbon Engine Technologies

...ries can work together. In launching this pre-competitive consortium based research program, we aim to enable participating companies to pull-forward robust solutions to some of the fundamental challenges we face in delivering new standards in fuel efficiency and reduced CO2." The consortium announ...

Sanofi-aventis Announces Second Quarter 2009 Results

...((R)) , the leading low molecular weight heparin on the market, returned to robust growth in the second quarter of 2009 with net sales up 13.3% at euro 780 m...(R)) , No-Spa ((R)) , Enterogermina ((R)) , Lactacyd ((R)) ) achieved robust growth of 12.9% and represented 38% of OTC net sales. Russia and Mexico rep...

Digitas Health Expands Adding Two Key Locations

...ompany, Tiedemann standardized the user experiences across multiple brands for a major client. With the abundance of life science companies and robust selection of universities and leading scientific research institutions, Boston ranks number one on the list of the largest life science clusters in th...

GlaxoSmithKline Completes Acquisition of Stiefel

...resent an 8% share of the global prescription dermatology market. Stiefel is committed to improving and developing new treatments and has a robust development pipeline, with more than 15 projects in late-stage development across a wide variety of dermatological conditions, such as acne, dermatose...

Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients

...ostic applications and is expected to introduce the product in Europe in late 2009. The assay is not available in the United States. NGAL is a small, robust protein produced by the kidney tubules and appears in urine just two-to-four hours following acute kidney injury (AKI), up to 46 hours sooner than cur...

Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders

...nDB databases is a powerful resource for Axial," said Kenneth Ward, M.D., chairman of the board and chief scientific officer of Axial Biotech. "With a robust library of family histories and linked diseases at our finger tips, we aim to define the genetic makeup of spinal disorders in an effort to develop di...

Quantros ACE Helps East Jefferson General Hospital Achieve Best-in-Class Performance

...loser to its goal of achieving best-in-class performance in every department. "EJGH has achieved broader staff engagement and gained access to robust reporting through the use of Quantros ACE," said Janet Davis, PT, MPH, FACHE, Organizational Effectiveness Director at EJGH. "By streamlinin...

Essilor : First Half 2009 Revenue

... year due to delays in delivering the new Mr Blue(TM) edger. In North America, business with optometrists and independent laboratories remained robust in the United States, while operations in Canada have begun to improve. Operations in the Asia-Pacific region had a good first-half, with India...

American Medical Informatics Association (AMIA) Submits Comments to Hit Policy Committee About Meaningful Use and Electronic Health Record Certification

... EHR certification should focus on process and care improvements over time No EHRs should be certified that are incapable of evolving into more robust versions Certification should work towards evidence-based standards for EHRs implementations Continued research and evaluation are needed...

ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens

...significantly advances our cancer immunotherapy capabilities and represents our continued commitment to developing our DepoVax(TM) technology within a robust clinical trial program." "This agreement combines our antigen discovery expertise with IVT's product development capabilities and we are pleased to ...

GPhA Says BIO Cries Wolf on Senate Biogenerics Proposal

...mission (FTC) report that such long periods of exclusivity are NOT needed to spark innovation. In fact, FTC suggested that because of their extremely robust intellectual property protection in this sector, 'no' to little market exclusivity is required. "Both the White House and the Office of Managem...

PharmSource Releases White Paper on Role of U.S. Foreign Corrupt Practices Act (FCPA) in the Bio/Pharma Industry

...ucted. Readers will find this timely publication to be a critical first step in understanding FCPA practices and ensuring the protection afforded by a robust compliance program, especially while conducting business in emerging markets. "[After all, it is far easier to start a compliance program be...

New Drug Application for Exenatide Once Weekly Accepted for Review by FDA

...s. Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes' robust pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous s...

VisEn Launches New Cat-K FAST(TM) Fluorescence Molecular Imaging Agent

... agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts in vivo . VisEn now offer... its Fluorescence Molecular Tomography (FMT (TM) ) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing a...

Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)

...armaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty bus...

IKARIA(R) to In-License BioLineRx's BL-1040

...About BioLineRx BioLineRx, a clinical stage drug development company traded on the Tel Aviv Stock Exchange (TASE: BLRX), is dedicated to building a robust pipeline of promising therapeutics for unmet medical needs. The Company's leading programs are BL-1020 for the treatment of schizophrenia and BL-1040 ...

Bay Area Youth to Represent ALS Patients at Giants' and Angels' Baseball Games on July 4th

...amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), as soon as possible. Focused on meeting this urgent unmet medical need, ALS TDI executes a robust discovery program, as well as a multi-pronged approach to validate potential therapeutics; including small molecules, protein biologics, gene therapie...

Global Small Molecule Kinase Inhibitors Market to Reach $16.2 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.

...en the period 2010 and 2015, as stated by the new market research report. New generation kinase inhibitor drugs like Nexavar are forecast to witness robust growth over the period 2006 through 2015. Leading players operating in the marketplace include Amgen Inc, Novartis, AstraZeneca plc, Genentech, ...

Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market

...armaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty bus...

World Nanomedicine Market to Cross $160 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

... GIA announces the release of a comprehensive global report on Nanomedicine markets. The global Nanomedicine market continues to register robust growth largely fueled by unique properties of nanoparticles that provide novel and improved advantages, introduction of novel products, healthy rise i...

KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)

...ng drugs to market faster and more efficiently. KBI is recognized for its track record in advancing its clients' drug programs by developing scalable, robust processes that result in more stable, active products. Joseph McMahon, President and CEO of KBI Biopharma notes, "We recognize the significant m...

First-Ever Egg Donor Web Portal Becomes One of The Largest Resources for Aspiring Parents in the U.S.

...-cultural egg donor candidates. Launched just over three months ago and already generating widespread industry recognition, the DNA website is a robust portal of potential egg donors listed with agencies throughout the entire U.S. In order to find the perfect donor, the comprehensive yet easy-to-use d...

Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine

...ine Research, University of Pittsburgh . "Not only did the vaccine induce robust HAI responses, it also induced HA-specific CD8+ T cell responses that were ...," said Dr. Rahul Singhvi, president and CEO of Novavax. "We also observed robust HAI responses among subjects in the clinical trial of our seasonal flu vacc...

Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August

...n osteoporotic fracture in her remaining lifetime. Although osteoporosis treatments are available, there remains a need for other options that deliver robust efficacy and support adherence to therapy," said Sean Harper, M.D., chief medical officer and head of Global Development at Amgen. "Likewise, there i...

Virtify, Inc. Delivers Industry's First Enterprise Content Compliance Software Suite for Life Sciences Companies

...nt and founder of Virtify. "Effectively managing these processes directly impacts a life sciences company's ability to compete. Virtify's flexible and robust solution is built specifically to streamline compliance processes, enabling enormous time and cost efficiencies, while bringing higher quality product...

Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer

...rch and represents our continued commitment to developing Stimuvax within a robust clinical trial program across several cancer types. We are very excited tha...inical Development Unit Oncology, Merck KGaA. "We are very pleased by the robust development program our partner, Merck KGaA, is conducting for Stimuvax," s...

BioSyntech Reports Positive Results from Pivotal Trial for BST-CarGel(R) Cartilage Repair Device

...erts who reviewed the data. He commented, "This randomized controlled study performed under good clinical practice guidelines is a well run study with robust data that will have an impact on scaffold directed cartilage repair in the coming years. I congratulate the Company on this early stage histological d...